key: cord-0933248-g9hbkoxw
authors: Marino, Achille; Romano, Micol; Gattinara, Maurizio; Cimaz, Rolando
title: Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members
date: 2020-10-02
journal: Semin Arthritis Rheum
DOI: 10.1016/j.semarthrit.2020.09.012
sha: 1c532c4c315edeb5401ab59b314bc32f1a5aa485
doc_id: 933248
cord_uid: g9hbkoxw

nan

We read with great interest the study by Michelena et al [1] investigating the incidence of the Coronavirus 19 disease (COVID-19) among adult and pediatric patients with rheumatic disease receiving anti-rheumatic drugs. They found an incidence rate comparable with general populations and they did not observe an increased risk of severe COVID-19. To support the notion that these patients do not show an increased susceptibility to COVID-19 compared to healthy peers, we report four patients diagnosed with juvenile idiopathic arthritis (JIA) exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while receiving TNF inhibitors (TNFi).

During our outpatient clinics we collected data from JIA patients on TNFi with at least one COVID-19 case among households (confirmed or highly suspected) followed in the Unit of Pediatric Rheumatology of ASST G. Pini Hospital, Milan, Italy from 1 st March to 31th May 2020.

A survey assessing the patients' health status, therapeutic changes and possible disease flares during the SARS-CoV-2 exposure was then administered by telephone. Demographical and clinical patients' data are shown in Table 1 At the outpatient visit before the COVID-19 exposure, all the patients were in disease remission.

During the COVID-19 exposure, patient 2 developed knee arthritis and uveitis requiring local steroids (intraarticular injection and eye drops) with a good response. Patient 4 complained of polyarthralgia (back, right hip and right midfoot); she had the longest time of TNFi discontinuation (16 weeks), while she restarted MTX after 2 weeks of discontinuation.

During this pandemic, the control of the underlying rheumatic disease is of primary importance given the increased infection susceptibility carried by an active inflammatory status [2] . Therefore, a careful evaluation of anti-rheumatic drug management assessing multiple factors (current disease activity and treatment, SARS-CoV-2 epidemiology in the patient's area, etc.) is advisable [3, 4] .

Our findings are in agreement with the hypothesis that JIA patients on TNFi do not show increased risk of severe COVID-19, although they might experience disease reactivation likely due to drug discontinuation [1, 5] . Larger studies are advisable to better characterize the role of TNFi in children and young adults with JIA exposed to SARS-CoV-2. RF: rheumatoid factor; ERA: enthesitis related arthritis; MTX: methotrexate; HCQ: hydroxychloroquine; RT-PCR: reverse-transcription-polymerase-chain-reaction test; NP swab: nasopharyngeal swab; a Hospitalized; b Mother hospitalized; c Interstitial pneumonia at X-ray; d Fever and diarrhea after which she developed complex regional pain syndrome of fifth metatarsal bone of the right foot, successfully treated with a sural nerve block.

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Risks associated with use of TNF inhibitors in children with rheumatic diseases

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1

Pediatric Rheumatology Group of the Milan Area. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs